Reality of obesity paradox: Results of percutaneous coronary intervention in Middle Eastern patients

Mohamad Jarrah1, Ayman J Hammoudeh2, Yousef Khader3

  • 11 Cardiology Section, Internal Medicine Department, King Abdullah University Hospital, Irbid, Jordan.

Insights

Obesity did not increase adverse cardiovascular events after percutaneous coronary intervention. Body mass index is a weak predictor of cardiovascular comorbidities in Arab Jordanian patients undergoing this procedure.

Area of Science:

  • Cardiology
  • Public Health
  • Obesity Research

Background:

  • Obesity is a growing global health concern associated with increased cardiovascular risk.
  • Understanding the impact of body mass index (BMI) on outcomes after percutaneous coronary intervention (PCI) is crucial for patient management.
  • Previous studies have shown mixed results regarding the association between obesity and cardiovascular events.

Purpose of the Study:

  • To compare baseline clinical characteristics, coronary angiographic features, and adverse cardiovascular events (ACEs) in obese versus overweight and normal/underweight patients undergoing PCI.
  • To evaluate the long-term impact of BMI on ACEs at 1-year follow-up.

Main Methods:

  • A prospective, multicenter study involving 2425 consecutive patients undergoing PCI.
  • Patients were categorized into three groups based on BMI: obese, overweight, and normal/underweight.
  • Data collected included clinical characteristics, angiographic findings, and incidence of ACEs during hospitalization and at 1-year follow-up.

Main Results:

  • Obese patients (28.8%) were more likely to be female and have higher rates of diabetes, hypertension, hypercholesterolemia, and prior PCI.
  • No significant differences were observed in the prevalence of multi-vessel coronary artery disease or multi-vessel PCI among the groups.
  • Rates of stent thrombosis, bleeding, and cardiac mortality were similar across all BMI groups during hospitalization and up to 1 year post-PCI.

Conclusions:

  • Major adverse cardiovascular event rates were comparable among obese, overweight, and normal/underweight patients following PCI.
  • BMI appears to be a weak risk factor for cardiovascular comorbidities in this Arab Jordanian population undergoing PCI.
  • These findings suggest that obesity alone may not significantly worsen outcomes after PCI in this specific demographic.

Related Concept Videos

Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
269
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
296
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
197
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.4K
Nursing Interventions I: Taxonomy of Nursing Interventions01:03

Nursing Interventions I: Taxonomy of Nursing Interventions

Nursing interventions are chosen as part of the planning process to achieve patient outcomes. Once nursing diagnoses are determined, the goals and outcomes are specified, then the nursing interventions are selected and individualized according to the patient's situation.
A nursing intervention is a treatment or action based on scientific concepts and knowledge from the nursing, behavioral, and physical sciences. Identifying and prioritizing nursing interventions based on the desired outcome...
4.0K
Nursing Interventions II: Selecting and Classifying the Nursing Interventions01:29

Nursing Interventions II: Selecting and Classifying the Nursing Interventions

Creating and executing a nursing diagnosis helps nurses plan care and guide patient, family, and community interventions. They are developed based on a patient's physical evaluation and support measuring the outcomes. It is not recommended to select random interventions throughout the planning process. Instead, consider the following six essential factors when choosing interventions:
3.4K